Paris, April 26, 2023 – 5:45 p.m. CEST – At its meeting of April 5, 2023, the Board of Directors of Mauna Kea Technologies (Euronext Paris, ISIN: FR0010609263, MKEA VIC) (the “Company”), inventor of the Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, decided to submit to the ordinary annual and extraordinary general meeting of shareholders to be held on June 2, 2023 the proposed transfer of the listing of its shares from the regulated market of Euronext Paris (Compartment C) to the Euronext Growth Paris multilateral trading facility, under its 13th resolution.
The transfer to Euronext Growth Paris would allow the Company to simplify its operations, reduce its listing costs while enabling it to continue to benefit from the advantages of the financial markets.
Provided this proposal is approved by the shareholders and that Euronext Paris SA agrees, the direct listing on Euronext Growth Paris will be carried out pursuant to an accelerated procedure for the admission to trading of the Company’s existing shares, without issuing any new shares. The Company meets the eligibility requirements for implementing such a transfer to Euronext Growth, namely a market capitalization of less than €1 billion and a free float of more than €2.5 million.
In accordance with the laws in force, Mauna Kea Technologies hereby informs its shareholders of the main possible consequences of this transfer.
For additional details, please see the full press release.
